A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects with Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission with First-Line Chemotherapy

This is a randomized, open-label, Phase 2 study of INCB024360 versus tamoxifen in women with histologically confirmed Federation of International Gynecologists and Obetetricians (FIGO) Stage III or IV epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube carcinoma (FTC) who have had biochemical-recurrence defined as an increasing CA-125 level that isgreater than theupper limit of normal (ULN) and successively increasing on 2 consecutive measurements at least 4 weeks apart without evidence of disease.

Study Number: 

PH 221912

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.